Company Directory - Almirall, S.A.
Company Details - Almirall, S.A.
Almirall, S.A.
WebsiteBarcelona, Spain
ISIN: ES0148754315
Almirall is a global biopharmaceutical company dedicated to skin health, focusing on developing innovative solutions for dermatological diseases. Through research and collaboration, Almirall aims to provide effective treatments that improve the quality of life for patients around the world.
CCI Score
CCI Score: Almirall, S.A.
57.57
-0.03%
Latest Event
Almirall Launches Act4Impact 2030 Sustainability Strategy
Almirall unveiled its 'Act4Impact 2030' sustainability strategy, which includes 20 strategic lines of action focused on achieving Zero Net Emissions through energy decarbonisation, sustainable mobility, enhanced supplier engagement, and the implementation of a Global 2030 Diversity, Equity and Inclusion (DEI) Plan.
Take Action
So what can you do? Support Almirall by shopping, spreading the word, or offering your support.
- Shop Alternatives
SEE ALL - Use Your Voice
OTHER TOOLS - Investigate
- Share the Score
SUPPORT CCI
LEADER
Almirall, S.A. is currently rated as a Leader.
Latest Events
- JUL042024
Almirall unveiled its 'Act4Impact 2030' sustainability strategy, which includes 20 strategic lines of action focused on achieving Zero Net Emissions through energy decarbonisation, sustainable mobility, enhanced supplier engagement, and the implementation of a Global 2030 Diversity, Equity and Inclusion (DEI) Plan.
+70
Labor Relations and Human Rights Practices
April 11
The introduction of a Global 2030 DEI Plan demonstrates Almirall’s commitment to elevating labor rights and inclusivity, crucial for protecting marginalized communities and countering authoritarian practices.
+60
Supply Chain Ethics
April 11
The strategy’s focus on enhanced supplier risk management and engagement practices signals a move towards ethical supply chain practices, reducing vulnerabilities and supporting sustainable, responsible business conduct.
- JUL022024
Almirall announced its updated sustainability strategy, Act4Impact 2030, which sets ambitious targets including a 50% reduction in direct greenhouse gas emissions, a comprehensive Diversity, Equity, and Inclusion plan, and sustainable supplier engagement initiatives. The strategy is positioned as part of the company’s commitment to environmental responsibility, ethical business practices, and improved patient outcomes.
+80
Business Practices and Ethical Responsibility
April 11
Almirall’s launch of the Act4Impact strategy demonstrates a robust commitment to sustainable business practices and ethical responsibility. The strategy's ambitious targets for decarbonization, tackling the gender pay gap, and reinforcing supplier sustainability protocols align with progressive, anti-fascist values by promoting environmental justice and social equity.
- JAN312024
On January 31, 2024, Almirall S.A. announced a three-year strategic partnership with Microsoft to drive digital transformation. The collaboration will leverage generative AI and advanced analytics to accelerate drug discovery and optimize data governance and operational processes in dermatology.
+50
Business Practices and Ethical Responsibility
April 11
The partnership with Microsoft demonstrates progressive business practices by integrating cutting‑edge digital tools to advance drug discovery and improve operational efficiency. This move is seen as a forward-thinking approach to bolstering patient care and research innovation.
+50
Technology and Services Impact
April 11
The integration of generative AI and advanced analytics underlines a significant shift towards innovative technologies in the pharmaceutical sector. This approach not only enhances drug discovery but also supports a transparent and efficient digital transformation, contributing positively to societal and ethical technological progress.
- JAN012021
Almirall’s Board of Directors approved a Global Procurement Policy in 2021 that emphasizes engaging only with suppliers whose practices meet ethical, sustainable, and socially responsible standards. The policy is designed to ensure a stable and transparent supply chain aligned with the company’s noble purpose, ultimately benefiting society and the planet.
+80
Supply Chain Ethics
April 11
The newly adopted procurement policy sets clear ethical and sustainability standards for supplier selection. By committing to work only with partners that share its values, Almirall proactively enhances supply chain ethics and promotes social responsibility, aligning with anti-fascist goals of corporate accountability and transparency.
- SEP162015
Almirall, S.A. is listed in the EU Transparency Register with the identifier 203884018809-66, having been first registered on 16 September 2015. The record details the company’s lobbying goals and remit, reflecting its standard engagement in advocacy and compliance with EU transparency regulations.
+0
Political Contributions and Lobbying Efforts
April 11
The company's registration on the EU Transparency Register is a routine disclosure of its lobbying activities. There is no evidence from the article that Almirall's lobbying efforts support any authoritarian or far‐right agendas. The information reflects standard compliance with regulatory requirements rather than an explicit effort to influence political outcomes in a problematic way.
Alternatives
Japan
26.16
Bagsværd, Denmark
18.81
Kenilworth, United States
2.89
Tokyo, Japan
-7.42
Basel, Switzerland
-19.75
Petah Tikva, Israel
-21.90
North Chicago, United States
-31.53
Indianapolis, United States
-35.34
Hyderabad, India
-53.10
Corporation
2.31
Corporate Financials
- Revenue
- 2022
- $800.00M
- Total Assets
- 2022
- $2.10B
- Operating Income
- 2022
- $180.00M
- Total Equity
- 2022
- $1.20B
Industries
- 324110
- Petroleum Refineries
- 325411
- Medicinal and Botanical Manufacturing
- 325412
- Pharmaceutical Preparation Manufacturing
